The info on Ethyol not working with IMRT is wrong -- our first radiation oncologist (now retired) was an expert on salivary gland preservation and also, use of amifostine. He did a lot of comparative in-house studies. His statistics were (this from our initial cnsult notes):

"IMRT -- can preserve about 50% salivary function
adding amifostine -- increases to 60-65% -- using tomoTherapy IMRT (most precise targeting) -- up to 75%. "

(Note that use of IMRT is actually the most important factor, the Ethyol only adds 10-15% improvement).

Our current RO says that he can, with careful planning, do almost as well with IMRT sans amifostine as with it (he finds a lot of people can't take the Ethyol or can't handle it for the full treatment course). He uses tomo whenever he can, but has had some problems with machine reliability.

Here is one study which looked at amifostine in a clinical setting: Antonadou et al. performed a randomized phase II trial of chemoradiation therapy with or without amifostine in 50 patients with advanced head and neck cancers.Chemotherapy consisted
of weekly carboplatin .The radiation dose was 2 Gy/d,to a total of 60